Stay updated with breaking news from Phase Iib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A novel TB vaccine candidate that could replace the bacille Calmette-Guerin vaccine and has been found to provide significantly better protection against the TB germ in South African newborns, is set to reach a new benchmark in the new year as it will be tested on teenagers and adults with latent TB.
GOTHENBURG, SE / ACCESSWIRE / December 12, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 12, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ...
Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last Vi